Please login to the form below

Not currently logged in
Email:
Password:

FDA calls for expanded Byetta precautions

The FDA has revealed it suspects a link between usage of Byetta (exenatide injection), a type 2 diabetes drug, and acute pancreatitis.

The FDA has revealed it suspects a link between usage of Byetta (exenatide injection), a type 2 diabetes drug, and acute pancreatitis.

The FDA said it reviewed 30 reports of acute pancreatitis in patients taking Byetta and added: "An association between Byetta and acute pancreatitis is suspected in some of these cases."

Officials said the maker of Byetta, Amylin, has agreed to include information about acute pancreatitis in the precautions section of the product's label.

"Healthcare professionals should be alert to the signs and symptoms of acute pancreatitis and instruct patients taking Byetta to seek prompt medical care if they experience unexplained, persistent, severe abdominal pain which may or may not be accompanied by vomiting," the FDA said.

On 10 October 2007, Amylin's co-marketing partner Lilly launched Byetta in India. India becomes the fourth major launch in the world after the US, UK and Germany where Byetta is now available.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics